Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Paratore, Sabrinaa; b | Banna, Giuseppe Luigic | D'Arrigo, Mariab | Saita, Salvatoreb | Iemmolo, Rosariob | Lucenti, Letiziab | Bellia, Domenicoa; b | Lipari, Helgab | Buscarino, Calogerob | Cunsolo, Rosariob | Cavallaro, Sebastianoa; b; *
Affiliations: [a] Functional Genomics Center, Institute of Neurological Sciences, Italian National Research Council, Catania, Italy | [b] Policlinico-Vittorio Emanuele, University Hospital, Catania, Italy | [c] Division of Medical Oncology, Cannizzaro Hospital, Catania, Italy
Correspondence: [*] Corresponding author: Sebastiano Cavallaro, M.D., Ph.D., Istituto di Scienze Neurologiche, CNR, Via Paolo Gaifami, 18, 95125 Catania, Italy. Tel.: +39 095 7436634; Fax: +39 095 7122426; E-mail: s.cavallaro@isn.cnr.it.
Abstract: Synchronous or metachronous brain metastases (BMs) occur in about 33% of patients affected by non-small-cell lung cancer (NSCLC). To date, no reliable biological marker is able to identify patients who will develop BMs. In the present study, using a quantitative double-labeling immunofluorescence analysis, we evaluated the expression of chemokine CXCL12 and its receptor, CXCR4, in primary NSCLC histological specimens of patients with and without BMs. The immunoreactivity of CXCL12 and CXCR4 was significantly higher in NSCLC samples of patients with BMs. We performed Receiver Operating Characteristics (ROC) analysis in order to define optimal cut-off values for CXCL12 and CXCR4 immunoreactivity that could discriminate between NSCLC patients without and with BMs. ROC curves showed a good diagnostic accuracy and adequate predictive power for both CXCL12 and CXCR4. These findings suggest a possible role for the CXCL12/CXCR4 axis in the metastatic evolution of NSCLC, and its potential use as prognostic markers and drug targets.
Keywords: Brain metastases, chemokines, CXCL12, CXCR4, immunohistochemistry, lung cancer, marker, metastasis, prognosis
DOI: 10.3233/CBM-2011-0232
Journal: Cancer Biomarkers, vol. 10, no. 2, pp. 79-89, 2012
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl